Not Yet RecruitingNot Applicable

Optimizing Endoscopic and Interventional Treatment for Portal Hypertensive Bleeding

1,066 participantsStarted 2026-03-17

Plain-language summary

This study aims to evaluate the impact of high-risk factors-such as elevated portal venous pressure, concurrent large extra-luminal vessels, portal vein thrombosis, and prominent portosystemic shunts-on the efficacy of endoscopic therapy. By comparing with interventional treatment, the goal is to optimize the clinical management protocol for esophageal and gastric varices, enhance the therapeutic outcomes of portal hypertension-related esophageal and gastric varices, and improve patient prognosis.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Admitted due to gastrointestinal bleeding and clinically diagnosed with portal hypertension * Underwent imaging examinations and gastroscopy within one week after admission * Gastroscopy revealed the presence of esophageal and/or gastric varices * Age over 18 years Exclusion Criteria: * Previous history of liver transplantation * Imaging or gastroscopy findings indicated ulcers or other causes of gastrointestinal bleeding * Concurrent severe life-threatening diseases involving the circulatory, hematological, or respiratory systems * Difficulty in follow-up, or lack of essential medical history information, imaging data, or other necessary records

What they're measuring

1-year gastrointestinal rebleeding rate

Timeframe: 1 year after the treatment.

Trial details

NCT IDNCT07502729

SponsorShanghai Zhongshan Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-12-31

View on ClinicalTrials.gov More Portal Hypertension trials